PMGC Secures Structured Royalty Payments from Elevai Skincare Sale — PMGC Holdings Inc.

Event summary

PMGC Holdings Inc. has secured a five-year royalty stream from the sale of its Elevai Skincare business, converting a 5% net sales royalty into scheduled monthly cash payments.
The agreement with Longevity Health Holdings includes interest-bearing payments starting October 15, 2026, and continuing until August 28, 2031.
The deal covers all future royalty and earnout payments, with mandatory prepayments tied to Longevity's capital events and annual audit rights.
PMGC's subsidiary, NorthStrive Biosciences, will receive the payments directly, ensuring recurring, non-dilutive cash flow.

The big picture

This agreement underscores PMGC's strategy of structuring transactions to capture long-term value from divestitures. By converting royalty entitlements into contractual cash flow, PMGC avoids dilution and debt while maintaining participation in Elevai Skincare's commercial performance. The deal aligns with broader trends in diversified holding companies leveraging non-dilutive financing to support growth.

What we're watching

Cash Flow Stability: How the structured royalty payments will impact PMGC's financial stability and its ability to focus on core businesses.
Elevai Performance: Whether Elevai Skincare's net sales will meet expectations, affecting the royalty payments and PMGC's recurring revenue.
Capital Events: The pace at which Longevity Health Holdings' capital raises or asset sales will trigger mandatory prepayments, accelerating cash recovery for PMGC.